Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLUD1 inhibitor (Leuven Centre for Drug Design and Discovery)
- Development stage
- Preclinical
- Lead developer
- Leuven Centre for Drug Design and Discovery
- Modality
- Small Molecules
01
Overview
GLUD1 inhibitor (Leuven Centre for Drug Design and Discovery) is a small molecule candidate currently in preclinical development for the treatment of aging and muscle wasting (sarcopenia). Developed by the Leuven Centre for Drug Design and Discovery (CD3), the drug targets glutamate dehydrogenase 1 (GLUD1), a mitochondrial enzyme responsible for the oxidative deamination of glutamate to alpha-ketoglutarate. By inhibiting GLUD1, the therapy aims to intervene in metabolic pathways that drive muscle atrophy and age-related functional decline. The project is part of CD3's strategic focus on translating academic research into novel therapeutic leads.
- Other names
- GLUD1 inhibitorGLUD-1 inhibitorGLUD 1 inhibitor
02
Targets
GLUD1 (Glutamate dehydrogenase 1, mitochondrial)
Beyond the preview
Go deeper on GLUD1 inhibitor (Leuven Centre for Drug Design and Discovery).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLUD1 inhibitor (Leuven Centre for Drug Design and Discovery).